These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 6860615)
41. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer. Ahmann DL; Carr DT; Coles DT; Hahn RG Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501 [TBL] [Abstract][Full Text] [Related]
42. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. Brem H; Tamargo RJ; Olivi A; Pinn M; Weingart JD; Wharam M; Epstein JI J Neurosurg; 1994 Feb; 80(2):283-90. PubMed ID: 8283268 [TBL] [Abstract][Full Text] [Related]
43. The role of minocycline in the treatment of intracranial 9L glioma. Weingart JD; Sipos EP; Brem H J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527 [TBL] [Abstract][Full Text] [Related]
44. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409 [TBL] [Abstract][Full Text] [Related]
45. Fluorouracil therapy of intraocular Greene melanoma in the rabbit. Olsen KR; Blumenkranz M; Hernandez E; Hajek A; Hartzer M Arch Ophthalmol; 1988 Jun; 106(6):812-5. PubMed ID: 3370010 [TBL] [Abstract][Full Text] [Related]
46. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951 [TBL] [Abstract][Full Text] [Related]
47. Response of 9L rat brain tumor multicellular spheroids to single and fractionated doses of 1,3-bis(2-chloroethyl)-1-nitrosourea. Sano Y; Hoshino T; Barker M; Deen DF Cancer Res; 1984 Feb; 44(2):571-6. PubMed ID: 6692362 [TBL] [Abstract][Full Text] [Related]
48. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Nagarkatti M; Toney DM; Nagarkatti PS Cancer Res; 1989 Dec; 49(23):6587-92. PubMed ID: 2573418 [TBL] [Abstract][Full Text] [Related]
49. Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea. Crittenden D; Tranum BL; Haut A Chest; 1977 Sep; 72(3):372-3. PubMed ID: 891293 [TBL] [Abstract][Full Text] [Related]
50. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801 [TBL] [Abstract][Full Text] [Related]
51. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. Gonsalves CF; Eschelman DJ; Thornburg B; Frangos A; Sato T AJR Am J Roentgenol; 2015 Aug; 205(2):429-33. PubMed ID: 25905562 [TBL] [Abstract][Full Text] [Related]
52. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099 [TBL] [Abstract][Full Text] [Related]
53. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Lin SH; Kleinberg LR Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283 [TBL] [Abstract][Full Text] [Related]
54. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228 [TBL] [Abstract][Full Text] [Related]
55. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. Strasser JF; Fung LK; Eller S; Grossman SA; Saltzman WM J Pharmacol Exp Ther; 1995 Dec; 275(3):1647-55. PubMed ID: 8531140 [TBL] [Abstract][Full Text] [Related]
56. Nitrosoureas: a review of experimental antitumor activity. Schabel FM Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694 [TBL] [Abstract][Full Text] [Related]
57. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. Kim GY; Tyler BM; Tupper MM; Karp JM; Langer RS; Brem H; Cima MJ J Control Release; 2007 Nov; 123(2):172-8. PubMed ID: 17884232 [TBL] [Abstract][Full Text] [Related]
58. [Experimental study of the action of olivomycin on a melanoblastoma of the vascular tract of the eye]. Nifontova TP Antibiotiki; 1978 Aug; 23(8):736-40. PubMed ID: 686699 [TBL] [Abstract][Full Text] [Related]
59. Chemotherapeutic activity and histopathologic feature of BCNU + 5-FU effect on Lewis lung carcinoma. Greco C; Calabresi F; Corsi A; Pericoli N; Caputo M Neoplasma; 1980; 27(3):279-87. PubMed ID: 7453848 [TBL] [Abstract][Full Text] [Related]
60. Water soluble derivatives and bifunctional analogs of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Fiebig HH; Eisenbrand G; Zeller WJ; Deutsch-Wenzel T Eur J Cancer (1965); 1977 Sep; 13(9):937-45. PubMed ID: 913476 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]